The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair

Published:2005-01-23 Issue:2 Volume:7 Page:195-201
ISSN:1465-7392
Container-title:Nature Cell Biology
language:en
Short-container-title:Nat Cell Biol

Author:

Sørensen Claus Storgaard,Hansen Lasse Tengbjerg,Dziegielewski Jaroslaw,Syljuåsen Randi G.,Lundin Cecilia,Bartek Jiri,Helleday Thomas

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology

Link

http://www.nature.com/articles/ncb1212.pdf

Reference32 articles.

1. Abraham, R. T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 15, 2177–2196 (2001).

2. Bartek, J. & Lukas, J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3, 421–429 (2003).

3. West, S. C. Molecular views of recombination proteins and their control. Nature Rev. Mol. Cell Biol. 4, 435–445 (2003).

4. Saintigny, Y. et al. Characterization of homologous recombination induced by replication inhibition in mammalian cells. EMBO J. 20, 3861–3870 (2001).

5. Liu, Q. et al. Chk1 is an essential kinase that is regulated by Atr and required for the G2/M DNA damage checkpoint. Genes Dev. 14, 1448–1459 (2000).

Cited by 567 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhanced pharmacological activities of AKR1C3‐activated prodrug AST‐3424 in cancer cells with defective DNA repair;International Journal of Cancer;2024-09-07

2. The Potential for Targeting G2/M Cell Cycle Checkpoint Kinases in Enhancing the Efficacy of Radiotherapy;Cancers;2024-08-29

3. Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer;Frontiers in Oncology;2024-08-02

4. Polymerase theta is a synthetic lethal target for killing Epstein-Barr virus lymphomas;Journal of Virology;2024-07-23

5. ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors;British Journal of Cancer;2024-07-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3